Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| |  Online-Ressource |
|---|
| Verfasst von: | Witzens-Harig, Mathias [VerfasserIn]  |
|---|
| | Memmer, Marie-Luise [VerfasserIn] |
|---|
| | Dreyling, Martin [VerfasserIn] |
|---|
| | Hess, Georg [VerfasserIn] |
|---|
| Titel: | A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial |
|---|
| Verf.angabe: | Mathias Witzens-Harig, Marie Luise Memmer, Martin Dreyling and Georg Hess |
|---|
| E-Jahr: | 2013 |
|---|
| Jahr: | 25 June 2013 |
|---|
| Umfang: | 5 S. |
|---|
| Fussnoten: | Gesehen am 18.11.2021 |
|---|
| Titel Quelle: | Enthalten in: BMC cancer |
|---|
| Ort Quelle: | London : BioMed Central, 2001 |
|---|
| Jahr Quelle: | 2013 |
|---|
| Band/Heft Quelle: | 13(2013), Artikel-ID 308, Seite 1-5 |
|---|
| ISSN Quelle: | 1471-2407 |
|---|
| Abstract: | The current standard treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma (DLBCL) primarily consists of intensified salvage therapy and, if the disease is chemo-sensitive, high dose therapy followed with autologous stem cell transplantation. In the rituximab era however, this treatment approach has shown only limited benefit. In particular, patients relapsing after rituximab-containing primary treatment have an adverse prognosis, especially if this occurs within the first year after therapy or if the disease is primarily refractory. Therefore there is an ultimate need for improved salvage treatment approaches. |
|---|
| DOI: | doi:10.1186/1471-2407-13-308 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1186/1471-2407-13-308 |
|---|
| | DOI: https://doi.org/10.1186/1471-2407-13-308 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Autologous Stem Cell Transplantation |
|---|
| | Mantle Cell Lymphoma |
|---|
| | Maximum Tolerate Dose |
|---|
| | Overall Response Rate |
|---|
| | Temsirolimus |
|---|
| K10plus-PPN: | 1777942713 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬A¬ phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial / Witzens-Harig, Mathias [VerfasserIn]; 25 June 2013 (Online-Ressource)
68803105
